Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis

Currently, anti-angiogenic agents (AAs) and immunotherapy are major components of standard therapies for patients with advanced non-small cell lung cancer (NSCLC). Several molecular-targeted agents that target the receptors of vascular endothelial growth factor (VEGF) have achieved positive outcomes. Bevacizumab plus platinum-doublet chemotherapy has become the standard treatment for patients with treatment-na ïve advanced NSCLC [1]. Further, ramucirumab or nintedanib plus chemotherapy have been approved by the Food and Drug Administration for previously treated advanced NSCLC [2,3].

Source: Lung Cancer - November 17, 2021 Category: Cancer & Oncology Authors: Kinnosuke Matsumoto, Takayuki Shiroyama, Tomoki Kuge, Kotaro Miyake, Yuji Yamamoto, Midori Yoneda, Makoto Yamamoto, Yujiro Naito, Yasuhiko Suga, Kiyoharu Fukushima, Shohei Koyama, Kota Iwahori, Haruhiko Hirata, Izumi Nagatomo, Yoshito Takeda, Atsushi Kuma Source Type: research